SCHEMBL1060286

SCHEMBL1060286

O=Cc1ccn(-c2ccccc2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.56
CYP2C9 P11712 1/20 0.47
PTGS2 P35354 1/20 0.46
MAPT P10636 3/20 0.45
HTT P42858 2/20 0.45
TSHR P16473 2/20 0.45
HSD17B10 Q99714 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ALDH1A1 P00352 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 1/20 0.41
ATM Q13315 1/20 0.41
ELOVL1 Q9BW60 5/20 0.41
POLB P06746 1/20 0.41
LMNA P02545 1/20 0.40
KDM4E B2RXH2 2/20 0.39
NPC1 O15118 1/20 0.39
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23036953 0.82 MTOR (0.52) P2RX7CYP2C9HTTHSD17B10L3MBTL1
SCHEMBL12438818 0.81 HTT (0.46) P2RX7HTTALDH1A1KMT2ASMN1; SMN2
SCHEMBL16045938 0.81 ALDH1A1 (0.44) P2RX7PTGS2MAPTHTTHSD17B10
SCHEMBL23036951 0.80 MTOR (0.54) P2RX7CYP2C9MAPTHTTHSD17B10
SCHEMBL30970914 0.80 MTOR (0.54) P2RX7CYP2C9MAPTHTTHSD17B10
SCHEMBL20422254 0.80 HTT (0.45) P2RX7CYP2C9MAPTHTTTSHR
SCHEMBL9978532 0.79 ALDH1A1 (0.50) P2RX7CYP2C9ALDH1A1SMN1; SMN2GAA
SCHEMBL4251316 0.79 MEN1 (0.54) P2RX7MAPTHTTL3MBTL1ALDH1A1
SCHEMBL17261501 0.77 NPC1 (0.53) CYP2C9MAPTHTTTSHRHSD17B10
SCHEMBL17261502 0.77 NPC1 (0.53) CYP2C9MAPTHTTTSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113164458-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-13 CN claimed
US-11597728-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-03-07 US claimed
EP-3856179-A1 MONOACYLGLYCEROL LIPASE MODULATORS Janssen Pharmaceutica N.V. (BE) 2021-08-04 EP claimed
US-20200102311-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2020-04-02 US claimed
WO-2020065614-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-04-02 WO claimed
US-12600717-B2 Tricyclic compounds as inhibitors of KRAS INCYTE CORPORATION (US) 2026-04-14 US disclosed
US-20240327410-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2024-10-03 US disclosed
CN-113164458-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-13 CN disclosed
CN-112368279-B Novel compounds as mTOR inhibitors and uses thereof 医药生命融合研究团 2024-05-28 CN disclosed
US-11993601-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV 2024-05-28 US disclosed
EP-4370515-A1 TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS Incyte Corporation (US) 2024-05-22 EP disclosed
CN-111892601-B Pyridopyrazolocinnoline compound and preparation method and application thereof 陕西大美化工科技有限公司 2023-09-26 CN disclosed
EP-1594438-A2 USE OF AN INHIBITOR OF 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE IN ORDER TO STIMULATE PIGMENTATION OF THE SKIN OR SKIN APPENDAGES L'OREAL (FR) 2005-11-16 EP disclosed
EP-1565150-A1 COMPOSITION FOR HAIR CARE OR EYELASHES CONTAINING A PYRAZOL-CARBOXAMIDE, ITS USE FOR STIMULATING HAIR AND EYELASH GROWTH AND/OR FOR PREVENTING LOSS THEREOF L'OREAL (FR) 2005-08-24 EP disclosed
WO-2005040127-A1 NOVEL COMPOUNDS AS AGONIST FOR PPAR GAMMA AND PPAR ALPHA, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME LG LIFE SCIENCES LTD. (KR) 2005-05-06 WO disclosed
US-20040235831-A1 Composition for caring for the hair or the eyelashes, containing a pyrazolecarboxamide compound, use thereof for stimulating the growth of the hair and the eyelashes and/or for reducing their loss SOCIETE L'OREAL, S.A. (FR) 2004-11-25 US disclosed
WO-2004073594-A2 USE OF AN INHIBITOR OF 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE IN ORDER TO STIMULATE PIGMENTATION OF THE SKIN OR SKIN APPENDAGES L'OREAL (FR) 2004-09-02 WO disclosed
WO-2004047776-A1 COMPOSITION FOR HAIR CARE OR EYELASHES CONTAINING A PYRAZOL-CARBOXAMIDE, ITS USE FOR STIMULATING HAIR AND EYELASH GROWTH AND/OR FOR PREVENTING LOSS THEREOF L'OREAL (FR) 2004-06-10 WO disclosed
CN-1289326-A N-[(substituted five-membered di-or thiaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia PFIZER PROD INC (US) 2001-03-28 CN disclosed
CN-1153779-A 2-(4-pyrazoloxy-pyrimidin-5-yl) acetic acid derivatives SANDOZ LTD (CH) 1997-07-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12600717-B2 Tricyclic compounds as inhibitors of KRAS KRAS, NRAS, HRAS P2RX7 4046/4885CYP2C9 2480/4885PTGS2 4449/4885
US-11993601-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP P2RX7 1597/4885CYP2C9 773/4885PTGS2 984/4885
US-20200102311-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP P2RX7 1597/4885CYP2C9 773/4885PTGS2 984/4885
US-11597728-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP P2RX7 1597/4885CYP2C9 773/4885PTGS2 984/4885
US-20240327410-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP P2RX7 1597/4885CYP2C9 773/4885PTGS2 984/4885
US-20040235831-A1 Composition for caring for the hair or the eyelashes, containing a pyrazolecarboxamide compound, use thereof for stimulating the growth of the hair and the eyelashes and/or for reducing their loss BCOR, HCRTR1, RCOR1 P2RX7 2136/4885CYP2C9 2023/4885PTGS2 3679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.